Cardiovascular Drugs: No Negative Impact on Myeloma Survival, Study Finds

New international research indicates that commonly prescribed cardiovascular medications, such as statins, diuretics, and blood pressure drugs, generally do not negatively affect survival among individuals with multiple myeloma. This significant finding, challenging previous assumptions, was published in Scientific Reports. The study involved a collaborative effort among scientists and oncologists from the United States, Australia, Qatar, and the United Arab Emirates.

Research Methodology

Researchers meticulously analyzed data from three major Phase III clinical trials in multiple myeloma: MAIA, POLLUX, and CASTOR. These trials collectively included a total of 1,804 patients.

The study's primary objective was to assess whether participants already taking widely used cardiovascular drug classes at the initiation of myeloma treatment experienced differences in critical outcomes. These outcomes included progression-free survival, overall survival, or the rate of serious adverse events. Cardiovascular drug classes evaluated encompassed antihypertensives, beta-blockers, ACE inhibitors, diuretics, and statins.

Key Observations

Most cardiovascular medication classes examined were not associated with worse survival outcomes after adjusting for various clinical factors.

However, a notable observation emerged: the use of ACE inhibitors or angiotensin receptor blockers (ARBs) was linked to both longer progression-free survival and a higher incidence of severe (grade 3) adverse events, specifically kidney-related and metabolic complications.

Clinical Recommendations

While ACE inhibitors/ARBs demonstrated indications of better disease control before myeloma progression, their associated increase in serious side effects necessitates careful monitoring.

Clinicians are strongly advised to pay closer attention to safety parameters, particularly kidney function and metabolic indicators, in patients receiving these agents during myeloma therapy. This vigilance is especially crucial for older or more vulnerable individuals.

Researchers emphasize that these findings do not warrant automatic discontinuation of these medications, but rather smarter monitoring and further study.

Future Research Directions

The study underscores the critical need for more systematic collection and analysis of concomitant medications in both oncology trials and real-world patient registries.

Future research aims to delve deeper, evaluating factors such as dose, duration, adherence, treatment changes, and interactions with specific myeloma regimens. The ultimate goal is to develop practical, risk-stratification approaches for cardiovascular drug use in myeloma patients, ensuring optimal care and safety.